ATE275556T1 - Imidazole derivate und ihre anwendung als cytokine inhibitore - Google Patents

Imidazole derivate und ihre anwendung als cytokine inhibitore

Info

Publication number
ATE275556T1
ATE275556T1 AT93904624T AT93904624T ATE275556T1 AT E275556 T1 ATE275556 T1 AT E275556T1 AT 93904624 T AT93904624 T AT 93904624T AT 93904624 T AT93904624 T AT 93904624T AT E275556 T1 ATE275556 T1 AT E275556T1
Authority
AT
Austria
Prior art keywords
alkyl
halo
substituted
naphth
aryl
Prior art date
Application number
AT93904624T
Other languages
English (en)
Inventor
Jerry Leroy Adams
Timothy Francis Gallagher
John C Lee
John Richard White
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE275556T1 publication Critical patent/ATE275556T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT93904624T 1992-01-13 1993-01-13 Imidazole derivate und ihre anwendung als cytokine inhibitore ATE275556T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81955192A 1992-01-13 1992-01-13
US86724992A 1992-04-10 1992-04-10
PCT/US1993/000674 WO1993014081A1 (en) 1992-01-13 1993-01-13 Imidazole derivatives and their use as cytokine inhibitors

Publications (1)

Publication Number Publication Date
ATE275556T1 true ATE275556T1 (de) 2004-09-15

Family

ID=27124382

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99201468T ATE294795T1 (de) 1992-01-13 1993-01-13 Substituierte imidazole derivate und ihre verwendung als cytokin inhibitore
AT93904624T ATE275556T1 (de) 1992-01-13 1993-01-13 Imidazole derivate und ihre anwendung als cytokine inhibitore

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99201468T ATE294795T1 (de) 1992-01-13 1993-01-13 Substituierte imidazole derivate und ihre verwendung als cytokin inhibitore

Country Status (21)

Country Link
US (1) US5686455A (de)
EP (2) EP0623126B1 (de)
JP (2) JP3298641B2 (de)
CN (1) CN1083473A (de)
AT (2) ATE294795T1 (de)
AU (1) AU671271B2 (de)
BG (1) BG98902A (de)
BR (1) BR9305809A (de)
CA (4) CA2127876C (de)
CZ (1) CZ168894A3 (de)
DE (2) DE69333805T2 (de)
ES (2) ES2242351T3 (de)
FI (1) FI943319A7 (de)
HU (1) HUT69714A (de)
IL (1) IL104369A0 (de)
MX (1) MX9300141A (de)
NO (1) NO942618L (de)
NZ (1) NZ249301A (de)
OA (1) OA09963A (de)
SK (1) SK83594A3 (de)
WO (1) WO1993014081A1 (de)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
ES2053401B1 (es) * 1992-01-13 1995-03-01 Smithkline Beecham Corp Compuestos de imidazol y procedimientos para su prepacion.
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5783664A (en) * 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
ATE252094T1 (de) * 1994-12-13 2003-11-15 Hoffmann La Roche Imidazol derivate mit proteinkinase, insbesondere egf-r tyrosinkinase, inhibierender wirkung
PL321292A1 (en) * 1995-01-12 1997-11-24 Smithkline Beecham Corp Novel xchemical compounds
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
CA2502764A1 (en) 1995-08-22 1997-03-06 Japan Tobacco Inc. Amide compounds
IL123950A (en) * 1995-10-06 2001-04-30 Merck & Co Inc Substituted imidazoles having anti-cancer and cytokine inhibitory activity and pharmaceutical compositions containing them
US6083949A (en) * 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
WO1997016442A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5756499A (en) * 1996-01-11 1998-05-26 Smithkline Beecham Corporation Substituted imidazole compounds
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
EP1005343A4 (de) * 1996-03-08 2000-06-07 Smithkline Beecham Corp Verwendung von csaids als inhibitoren der angiogenese
US6096748A (en) * 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
WO1997035856A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
WO1997035855A1 (en) 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
US6294541B1 (en) 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
AU708883B2 (en) * 1996-06-10 1999-08-12 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
HUP9903330A2 (hu) 1996-11-19 2000-03-28 Amgen Inc. Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények
CA2271893A1 (en) * 1996-11-20 1998-05-28 Linda L. Chang Triaryl substituted imidazoles as glucagon antagonists
EP0959885A4 (de) * 1996-11-20 2002-07-17 Merck & Co Inc Triaryl substituierte imidazole und verfahren zur verwendung
WO1998021957A1 (en) * 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
US5880139A (en) * 1996-11-20 1999-03-09 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
HUP0002842A3 (en) 1997-04-24 2002-01-28 Ortho Mcneil Pharm Inc Substituted imidazoles, process for producing them, pharmaceutical compositions containing them, their use and their intermediates
AU742293B2 (en) * 1997-06-12 2001-12-20 Aventis Pharma Limited Imidazolyl-cyclic acetals
US20020156104A1 (en) 1997-06-13 2002-10-24 Jerry L. Adams Novel pyrazole and pyrazoline substituted compounds
JP2002505690A (ja) 1997-06-19 2002-02-19 スミスクライン・ビーチャム・コーポレイション 新規なアリールオキシピリミジン置換イミダゾール化合物
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
AU8757098A (en) * 1997-06-30 1999-02-10 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US6251914B1 (en) 1997-07-02 2001-06-26 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US6362193B1 (en) 1997-10-08 2002-03-26 Smithkline Beecham Corporation Cycloalkenyl substituted compounds
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
BR9813998A (pt) 1997-11-19 2000-09-26 Kowa Co Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos
DE19882893T1 (de) 1997-12-12 2001-02-22 Euro Celtique Sa Herstellung von 3-substituierten Adeninen
JP2001526230A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
CA2321559A1 (en) * 1998-02-26 1999-09-02 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrrolobenzimidazoles for treating inflammatory diseases
BR9910621A (pt) 1998-05-22 2001-01-30 Smithkline Beecham Corp Novos compostos de imidazol 2-alquil substituìdos
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
EP1109918B1 (de) * 1998-06-24 2006-10-04 University of Dundee Mitogen- und stress-aktivierte proteinkinasen, die zwei kinase domänen enthalten, und deren verwendungen
AU4395399A (en) * 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
ES2221426T3 (es) * 1998-08-20 2004-12-16 Smithkline Beecham Corporation Nuevos compuestos de triazol sustituidos.
CZ297264B6 (cs) 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
DE19842833B4 (de) * 1998-09-18 2005-04-14 Merckle Gmbh 2-Arylalkylthio-imidazole, 2-Arylalkenylthio-imidazole und 2-Arylalkinylthio-imidazole als Entzündungs-Hemmstoffe und Hemmstoffe der Cytokin-Freisetzung
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6319928B1 (en) 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
US6239279B1 (en) * 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
EP1140083A4 (de) 1999-01-08 2004-01-02 Smithkline Beecham Corp Neue verbindungen
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
MXPA01008440A (es) 1999-02-22 2002-04-24 Boehringer Ingelheim Pharma Derivados heterociclicos policiclos como agentes anti-inflamatorios..
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
TR200102817T2 (tr) 1999-03-12 2002-05-21 Boehringer Ingelheim Pharmaceuticals, Inc. Antiinflamatuar ajanlar olarak faydalı bileşikler
WO2000055152A1 (en) 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
EP1169321A4 (de) 1999-04-02 2002-10-30 Euro Celtique Sa Purinderivate mit phosphodiesterase-inhibitor-aktivität
WO2000066124A1 (fr) * 1999-04-28 2000-11-09 Sankyo Company, Limited Agents preventifs ou inhibiteurs destines a une hepatopathie
DE60003550T2 (de) 1999-05-14 2004-04-15 Ortho-Mcneil Pharmaceutical, Inc. Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung
CA2374737C (en) * 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
US6610697B1 (en) 1999-11-10 2003-08-26 Ortho-Mcneil Pharmaceutical, Inc. Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
ES2230171T3 (es) 1999-11-23 2005-05-01 Smithkline Beecham Corporation Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
DE60023025T2 (de) 1999-11-23 2006-07-13 Smithkline Beecham Corp. 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
JP2003514900A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
AR029803A1 (es) * 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
CA2404384A1 (en) * 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
JP2004511554A (ja) 2000-10-18 2004-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 炎症性疾患の治療で有用な置換イミダゾール
AU2002246855B2 (en) 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
WO2002051442A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Concomitant drugs
ES2296910T3 (es) * 2001-01-22 2008-05-01 Sankyo Company, Limited Compuestos sustituidos con grupo amino biciclicos.
DE10107683A1 (de) * 2001-02-19 2002-08-29 Merckle Gmbh Chem Pharm Fabrik 2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
US6790846B2 (en) * 2001-05-24 2004-09-14 The Procter & Gamble Company Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
AU2002366644A1 (en) * 2001-12-11 2003-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. Method for administering birb 796 bs
EP1480973B1 (de) * 2002-02-25 2008-02-13 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
AU2003227276A1 (en) 2002-03-27 2003-10-08 Nippon Sigmax Co., Ltd. Cytokine controlling device, treating device and treating method
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2003245989A1 (en) 2002-07-09 2004-01-23 Boehringer Ingelheim Pharma Gmbh And Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
AU2003256297A1 (en) * 2002-08-09 2004-02-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
CN101870691A (zh) 2002-08-19 2010-10-27 劳洛斯治疗公司 2,4,5-三取代的咪唑及其作为抗菌剂的用途
DE10238045A1 (de) * 2002-08-20 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik 2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
WO2004063192A1 (en) * 2003-01-10 2004-07-29 Pharmacopeia Drug Discovery, Inc. Imidazolyl pyrimidine derivatives useful as il-8 receptor modulators
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
BRPI0408359A (pt) 2003-03-18 2006-03-21 Kowa Co derivados de fenilpiridazina solúveis em água e medicamentos contendo os mesmos
AU2004289539C1 (en) 2003-11-14 2012-06-07 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
JP2007516258A (ja) * 2003-12-12 2007-06-21 ワイス 心臓血管の疾患治療に有用なキノリン誘導体
WO2005063247A1 (en) * 2003-12-22 2005-07-14 Amgen Inc. Aryl sulfonamide compounds and uses related thereto
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
WO2006062069A1 (ja) * 2004-12-06 2006-06-15 Santen Pharmaceutical Co., Ltd. ｐ３８ＭＡＰキナーゼ阻害剤を有効成分とする掻痒治療剤
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
ATE538118T1 (de) 2004-12-28 2012-01-15 Aska Pharm Co Ltd Pyrimidinylisoxazolderivat
KR101327323B1 (ko) * 2005-01-14 2013-11-11 에스케이바이오팜 주식회사 옥사졸 하이드록삼산 유도체 및 이들의 용도
MY145281A (en) * 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
CA2611032C (en) 2005-05-25 2012-01-17 Genesense Technologies Inc. 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
TW201018662A (en) * 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
JP5244591B2 (ja) 2006-06-28 2013-07-24 あすか製薬株式会社 ピリジルイソオキサゾール誘導体
US20090192164A1 (en) * 2006-06-28 2009-07-30 Aska Pharmaceutical Co., Ltd. Treating agent of inflammatory bowel disease
KR101434706B1 (ko) 2007-02-16 2014-08-26 아스카 세이야쿠 가부시키가이샤 미립자 유성 현탁액을 포함하는 의약 조성물
WO2008133192A1 (ja) * 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8691866B2 (en) 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
PL2484661T3 (pl) 2009-09-30 2017-10-31 Toray Industries Pochodna 2,3-dihydro-1h-inden-2-ylomocznika i jej zastosowanie farmaceutyczne
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (de) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Festen formen von isochinolinonen
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
US20140163075A1 (en) * 2011-06-01 2014-06-12 Netherland Cancer Institute Modulation of the ubiquitin-proteasome system (ups)
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (de) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
TW201331194A (zh) * 2011-12-23 2013-08-01 Millennium Pharm Inc 雜芳基化合物及其用途
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014153464A2 (en) 2013-03-20 2014-09-25 Lorus Therapeutics Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
BR112015026519A2 (pt) 2013-04-19 2017-07-25 Astrazeneca Ab composto antagonista do receptor nk3 (nk3ra) para uso em um método destinado ao tratamento de síndrome do ovário policístico (sop)
EP3052102B1 (de) 2013-10-04 2019-12-04 Aptose Biosciences Inc. Zusammensetzungen zur behandlung von krebs
EP3964507A1 (de) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und verwendungen davon
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10813920B2 (en) 2013-11-14 2020-10-27 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (de) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Kombinationstherapie
FR3060987B1 (fr) * 2016-12-22 2020-10-02 Oreal Procede de coloration des fibres keratiniques mettant en oeuvre au moins un colorant triarylmethane particulier et au moins un colorant fluorescent
JP2021501203A (ja) 2017-10-30 2021-01-14 アプトース バイオサイエンシズ インコーポレイテッド がん治療用のアリールイミダゾール
WO2020124397A1 (en) 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
JP2024501625A (ja) * 2020-12-11 2024-01-15 ザ スクリプス リサーチ インスティテュート 神経変性、変性及び代謝性障害の処置のための化合物並びにその使用
CN119241502B (zh) * 2024-12-09 2025-02-28 四川大学华西医院 Nsd3降解剂及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
CH561202A5 (de) * 1971-05-10 1975-04-30 Ciba Geigy Ag
US4005614A (en) * 1975-11-13 1977-02-01 Samuel Moore And Company Motion transfer system
US4175127A (en) * 1978-09-27 1979-11-20 Smithkline Corporation Pyridyl substituted 2,3-dihydroimidazo[2,1-b]thiazoles
GR75287B (de) * 1980-07-25 1984-07-13 Ciba Geigy Ag
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
JP3264492B2 (ja) * 1992-01-13 2002-03-11 スミスクライン・ビーチャム・コーポレイション ピリジル置換イミダゾール

Also Published As

Publication number Publication date
DE69333616D1 (de) 2004-10-14
DE69333805T2 (de) 2006-01-19
EP0623126B1 (de) 2004-09-08
FI943319L (fi) 1994-09-12
US5686455A (en) 1997-11-11
AU3592393A (en) 1993-08-03
BR9305809A (pt) 1997-02-18
JP2002097189A (ja) 2002-04-02
CN1083473A (zh) 1994-03-09
SK83594A3 (en) 1995-03-08
CA2351694A1 (en) 1993-07-22
DE69333805D1 (de) 2005-06-09
HU9402092D0 (en) 1994-09-28
EP0943616A1 (de) 1999-09-22
CZ168894A3 (en) 1995-01-18
ES2227517T3 (es) 2005-04-01
CA2368862A1 (en) 1993-07-22
ES2242351T3 (es) 2005-11-01
MX9300141A (es) 1994-07-29
CA2314425A1 (en) 1993-07-22
WO1993014081A1 (en) 1993-07-22
AU671271B2 (en) 1996-08-22
JPH07503017A (ja) 1995-03-30
BG98902A (bg) 1995-06-30
IL104369A0 (en) 1993-05-13
CA2127876C (en) 2003-05-13
NO942618L (no) 1994-08-30
JP3298641B2 (ja) 2002-07-02
EP0943616B1 (de) 2005-05-04
NO942618D0 (no) 1994-07-12
CA2127876A1 (en) 1993-07-22
DE69333616T2 (de) 2005-09-08
HUT69714A (en) 1995-09-28
OA09963A (en) 1995-12-11
ATE294795T1 (de) 2005-05-15
FI943319A7 (fi) 1994-09-12
NZ249301A (en) 1996-06-25
FI943319A0 (fi) 1994-07-12
EP0623126A1 (de) 1994-11-09

Similar Documents

Publication Publication Date Title
DE69333616D1 (de) Imidazole derivate und ihre anwendung als cytokine inhibitore
NZ324007A (en) Quinazoline derivatives susbtituted by a phenyl and medicaments
DE3881472D1 (de) Heterocyclische verbindungen mit therapeutischer wirkung.
CA2282890A1 (en) Therapeutic heterocyclic compounds
ATE194340T1 (de) Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
ATE140698T1 (de) Diazotierte heterocyclische derivate aus stickstoff, substituiert durch eine biphenylgruppe, ihre herstellung, und diese enthaltende pharmazeutische zubereitungen
ATE247654T1 (de) Neue heterozyklische verbindungen
ATE318801T1 (de) Isoxazolin derivate und herbizide, die diese als aktiven bestandteil enthalten
TW200503692A (en) Therapeutic agents
AR035777A1 (es) Derivados de pirazol sustituidos, procesos para su preparacion, composiciones farmaceuticas que los contienen, y su uso en medicina
SE0201937D0 (sv) Therapeutic agents
MXPA05007494A (es) Nuevos compuestos.
BRPI0417157A (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
IL83681A0 (en) Dihydropyridines,their preparation and pharmaceutical compositions containing them
ATE224872T1 (de) Azetidinonderivate zur behandlung von hcmv entzündungen
ATE199253T1 (de) Antidepressiv wirkende 3-halophenylpiperazinyl- propylderivate von substituierten triazolonen und triazoldionen
ES8106905A1 (es) Procedimiento para preparar derivados de benzodiazepina
AR003416A1 (es) Nuevos derivados de acido hidroximico, procedimiento para preparar dichos derivados, compuestos intermediarios de aplicacion exclusiva en dichoprocedimiento, composiciones plaguicidas y procedimientos para el tratamiento de plantas con dichos derivados.
DK1023265T3 (da) Azetidinonderivater til behandlingen af HCMV infektioner
IT1213555B (it) 2 metiltiometildiidropiridine, un processo per laloro preparazione e composizioni farmaceutiche che le contengono.
NZ336368A (en) Substituted pyrazole-3-yl benzazoles and their use as herbicides
EA200400112A1 (ru) Замещенные 6-(2-толил) триазолопиримидины
DK0514935T3 (da) Hidtil ukendte bensopyranderivater og fremgangsmåder til fremstilling deraf
EA200400596A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ФЕНЕТИЛАМИДОВ α-КАРБОНОВЫХ ИЛИ α-ТИОКАРБОНОВЫХ КИСЛОТ

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties